Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

Jeffrey W. Meeusen, Leslie J. Donato, Allan S Jaffe

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

Original languageEnglish (US)
Article number48
JournalCurrent Cardiology Reports
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Acute Coronary Syndrome
Biomarkers
Lipids
Apolipoproteins B
Lipoprotein(a)
Ceramides
Omega-3 Fatty Acids
Lipoproteins
Guidelines
lipoprotein cholesterol
oxidized low density lipoprotein
Therapeutics

Keywords

  • Apolipoprotein B
  • Ceramides
  • Lipoprotein(a)
  • Non-HDL cholesterol
  • Omega-3
  • Oxidized LDL

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. / Meeusen, Jeffrey W.; Donato, Leslie J.; Jaffe, Allan S.

In: Current Cardiology Reports, Vol. 19, No. 6, 48, 01.06.2017.

Research output: Contribution to journalReview article

Meeusen, Jeffrey W. ; Donato, Leslie J. ; Jaffe, Allan S. / Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. In: Current Cardiology Reports. 2017 ; Vol. 19, No. 6.
@article{48c446f438614ee6bcbf580f4ca5030d,
title = "Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes",
abstract = "Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.",
keywords = "Apolipoprotein B, Ceramides, Lipoprotein(a), Non-HDL cholesterol, Omega-3, Oxidized LDL",
author = "Meeusen, {Jeffrey W.} and Donato, {Leslie J.} and Jaffe, {Allan S}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s11886-017-0863-9",
language = "English (US)",
volume = "19",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes

AU - Meeusen, Jeffrey W.

AU - Donato, Leslie J.

AU - Jaffe, Allan S

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

AB - Purpose of Review: The objective of this review was to summarize evidence gathered for the prognostic value of routine and novel blood lipids and lipoproteins measured in patients with acute coronary syndromes (ACS). Recent Findings: Data supports clear association with risk and actionable value for non-high-density lipoprotein (Non-HDL) cholesterol and plasma ceramides in a setting of ACS. The prognostic value and clinical actionability of apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] in ACS have not been thoroughly tested, while the data for omega-3 fatty acids and oxidized low-density lipoprotein (Ox-LDL) are either untested or more varied. Summary: Measuring basic lipids, which should include Non-HDL cholesterol, at the time of presentation for ACS is guideline mandated. Plasma ceramides also provide useful information to guide both treatment decisions and follow-up. Additional studies targeting ACS patients are necessary for apoB, Lp(a), omega-3 fatty acids, and Ox-LDL.

KW - Apolipoprotein B

KW - Ceramides

KW - Lipoprotein(a)

KW - Non-HDL cholesterol

KW - Omega-3

KW - Oxidized LDL

UR - http://www.scopus.com/inward/record.url?scp=85018478407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018478407&partnerID=8YFLogxK

U2 - 10.1007/s11886-017-0863-9

DO - 10.1007/s11886-017-0863-9

M3 - Review article

VL - 19

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

M1 - 48

ER -